BioStock interview

Date: 2024-04-11

As we could announce last week, all patients in the extension part (part B) of our phase 1b study, with the vaccine candidate ALZ-101, have now received their final dose. Based on this important milestone, Biostock contacted CEO Kristina Torfgård and Development Project Director Stefan Pierrou to learn more about Alzinova AB's next steps in the development of ALZ-101, pending the publication of the results of part B.